Dolasetron
A 5-HT3 receptor antagonist used to prevent and treat nausea and vomiting caused by chemotherapy, radiation therapy, and surgery. It works by blocking serotonin receptors in the gut and brain involved in triggering the vomiting reflex. It can prolong the QT interval on the ECG and should be used with caution in patients with cardiac risk factors.
Molekularmasse
324,4000 g/mol
LogP
3,40
TPSA
62,40 Ų
Lipinski-Regel der Fünf
Bestanden
Therapeutische Bereiche
Wirkmechanismus
Competitively binds to its target receptor without activating it, blocking the natural ligand from binding and preventing receptor-mediated signaling.
Pharmacokinetics (PK)
Pharmacodynamics (PD)
Competitively binds to its target receptor without activating it, blocking the natural ligand from binding and preventing receptor-mediated signaling.
2D-Struktur
Cite this structure
Embed this structure
SMILES
O=C(O[C@@H]1C[C@@H]2C[C@H]3C[C@H](C1)N2CC3=O)c1c[nH]c2ccccc12
InChI
InChI=1S/C19H20N2O3/c22-18-10-21-12-5-11(18)6-13(21)8-14(7-12)24-19(23)16-9-20-17-4-2-1-3-15(16)17/h1-4,9,11-14,20H,5-8,10H2/t11-,12-,13+,14+
Molecular Formula
C19H20N2O3
HBD / HBA
1 / 4
Rotierbare Bindungen
3
Schwere Atome
24
No targets recorded
Target interaction data is not yet available for this drug.
No interactions recorded
Drug interaction data is not yet available for this compound.
No side effects recorded
Side effect data is not yet available for this drug.
Häufig gestellte Fragen
A 5-HT3 receptor antagonist used to prevent and treat nausea and vomiting caused by chemotherapy, radiation therapy, and surgery. It works by blocking serotonin receptors in the gut and brain involved in triggering the vomiting reflex. It can prolong the QT interval on the ECG and should be used with caution in patients with cardiac risk factors.
Competitively binds to its target receptor without activating it, blocking the natural ligand from binding and preventing receptor-mediated signaling.
Yes, Dolasetron is an approved drug. It has reached clinical phase 4. It is classified as a Small molecule.
References & Data Sources
- ChEMBL — European Bioinformatics Institute (EBI). CHEMBL2368925. Open-access bioactivity database.
- PubChem — National Center for Biotechnology Information (NCBI). CID 3033818. Chemical information database.
Data aggregated from publicly available pharmacological databases. Last updated 2026-03-04.
Medizinischer Haftungsausschluss
This content is for educational and informational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making medication decisions.
Embed This Widget
Add the script tag and a data attribute to embed this widget.
<script src="https://cdn.jsdelivr.net/npm/drugfyi-embed@1/dist/embed.min.js" defer></script>
<div data-drugfyi="drug" data-slug="dolasetron"></div>Embed via iframe for maximum compatibility.
<iframe src="https://drugfyi.com/iframe/drug/dolasetron/" width="420" height="400" frameborder="0" style="border:0;border-radius:10px;max-width:100%" loading="lazy"></iframe>Paste this URL in WordPress, Medium, or any oEmbed-compatible platform.
https://drugfyi.com/drug/dolasetron/Add a dynamic SVG badge to your README or docs.
[](https://drugfyi.com/drug/dolasetron/)Use the native HTML custom element.
<script src="https://cdn.jsdelivr.net/npm/drugfyi-embed@1/dist/embed.min.js" defer></script>
<drugfyi-drug slug="dolasetron"></drugfyi-drug>